| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q4 2013 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS INC | 21 | Q2 2024 | 22.8% |
| PIERIS PHARMACEUTICALS INC | 20 | Q3 2023 | 7.1% |
| REGENXBIO INC | 19 | Q2 2024 | 14.3% |
| BLUEPRINT MEDICINES CORP | 18 | Q2 2024 | 17.3% |
| UNIQURE NV | 18 | Q1 2023 | 10.8% |
| MERUS N V | 17 | Q2 2024 | 13.0% |
| SPERO THERAPEUTICS INC | 16 | Q3 2022 | 15.8% |
| SPDR S&P BIOTECH ETF TR | 15 | Q4 2023 | 52.1% |
| ARGENX SE | 15 | Q3 2023 | 3.7% |
| GENMAB A/S | 13 | Q3 2023 | 3.9% |
View Aquilo Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| PRECISION BIOSCIENCES INC | March 18, 2024 | 466,767 | 7.1% |
| PIERIS PHARMACEUTICALS, INC. | February 14, 2024 | 1,126,761 | 1.1% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Spero Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Merus N.V. | February 14, 2020 | 814,505 | 2.8% |
| SYNLOGIC, INC.Sold out | February 14, 2020 | 0 | 0.0% |
View Aquilo Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-29 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-03-18 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
View Aquilo Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.